Editorial-Orientierung von MedAPI — kein Bestandteil der Kodieranweisung.
C24 encompasses primary malignancies of specified extrahepatic biliary sites, the ampulla of Vater, overlapping biliary tract sites, and the biliary tract when the site is unspecified. Primary gallbladder carcinoma is classified under C23, while intrahepatic bile duct carcinoma and certain documented perihilar or nonsite-specific cholangiocarcinomas are classified under C22.1 in ICD-10-CM.
Common Histologies
- Adenocarcinoma of the extrahepatic bile duct (extrahepatic cholangiocarcinoma when the extrahepatic site is documented)
- Ampullary adenocarcinoma, commonly intestinal or pancreatobiliary subtype
- Less commonly, adenosquamous, squamous, mucinous, or neuroendocrine carcinoma
Common Symptoms
- Painless jaundice (R17), dark urine (R82.91), pale stools (R19.5), or and pruritus (L29.9)
- Abdominal or right upper-quadrant discomfort (R10.11)
- Anorexia (R63.0), weight loss (R63.4), fatigue (R53.83), or nausea (R11.0)
- May present with biliary obstruction or ascending cholangitis (K83.1)
- Ampullary tumors may present earlier because small lesions can obstruct the distal bile duct (C24.1)
Diagnosis
Evaluation commonly includes liver biochemical tests and contrast-enhanced CT or MRI/MRCP. Endoscopic ultrasound, ERCP with brushings or biopsy, cholangioscopy, or percutaneous sampling may be used according to tumor location and resectability. Histologic confirmation is generally sought before nonsurgical systemic therapy, although surgery may occasionally proceed for a highly suspicious, resectable lesion when preoperative sampling is nondiagnostic.
Serum CA 19-9 and CEA may support assessment or follow-up but are not diagnostic. CA 19-9 can be elevated because of biliary obstruction or cholangitis.
Staging
Staging is site-specific and considers local invasion, regional lymph nodes, and distant metastases. Resectability also depends on longitudinal duct involvement and relationships to major vessels, the pancreas, duodenum, and liver. Distal extrahepatic bile duct and ampullary cancers have distinct staging systems and surgical considerations. Perihilar tumors also require specialized assessment of ductal, vascular, and hepatic involvement, although they may be classified outside C24 in ICD-10-CM depending on the documented terminology and site.
Molecular Markers
Comprehensive tumor profiling may be considered in advanced disease. Potentially relevant findings include mismatch-repair deficiency or microsatellite instability, HER2 amplification or overexpression, NTRK fusions, and alterations involving KRAS, BRAF, or other actionable pathways. IDH1 mutations and FGFR2 fusions are more characteristic of intrahepatic cholangiocarcinoma and are less common in extrahepatic tumors.
Common Treatments
- Surgical resection when disease is localized and technically resectable
- Pancreaticoduodenectomy for many distal extrahepatic bile duct and ampullary tumors
- Bile duct resection with hepatic resection for selected proximal or perihilar tumors; perihilar disease is included here for clinical completeness but may be classified outside C24 depending on documentation
- Adjuvant systemic therapy after resection in appropriate patients
- Systemic chemoimmunotherapy or chemotherapy for unresectable, recurrent, or metastatic disease
- Biomarker-directed therapy when a clinically actionable alteration is present
- Endoscopic or percutaneous biliary drainage, stenting, radiation therapy, and symptom-directed care as indicated
Scope Note
C24 identifies the primary anatomic site as another or unspecified part of the biliary tract. C24.0 includes documented extrahepatic sites such as the common bile duct, cystic duct, hepatic duct, sphincter of Oddi, and biliary passage not otherwise specified; C24.1 identifies the ampulla of Vater, and C24.9 identifies an unspecified biliary tract site.
C24.8 applies to a single tumor involving contiguous biliary sites—including combined intrahepatic and extrahepatic bile duct involvement—when the point of origin cannot be determined. Multifocal disease alone is not sufficient to establish an overlapping-site code.
Documented Klatskin/perihilar tumors and cholangiocarcinoma without further site specification are indexed to C22.1 in ICD-10-CM; C24.0 requires documentation of an extrahepatic bile duct site. Primary gallbladder cancer is classified under C23. C24 does not encode histologic subtype, grade, stage, resectability, or molecular findings, and metastasis to the biliary tract from another primary site is not coded as a primary C24 malignancy.